We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Repligen (NASDAQ: RGEN) shares are trading higher on Wednesday after the company reported better-than-expected first-quarter EPS and sales results.Replige reported quarterly earnings of 32 cents per share, which beat the analyst consensus estimate of 21 cents. The company reported quarterly sales of $76.1 million, which beat the analyst consensus estimate of $71.19 million.Repligen is a life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide.View more earnings on RGENRepligen shares were trading up 7.88% at $41.59 on Wednesday. The stock has a 52-week range between $125.44 and $65.62.Related Links:Gilead's Remdesivir Granted FDA Emergency Use To Treat COVID-19Volunteers Begin Testing Moderna Coronavirus VaccineSee more from Benzinga * Why Alpha Pro Tech's Stock Is Trading Higher Today * Why Barrick Gold's Stock Is Trading Lower Today * Shopify Reports Q1 Earnings Beat, Subs Revenue Grows 34%(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen Corporation (RGEN) today announced that the Company will report its first quarter 2020 financial results on Wednesday, May 6, 2020. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three-month reporting period ended March 31, 2020. The conference call will be accessible by dialing toll-free (844) 701-1063 for domestic callers and (412) 317-5487 for international callers.
In 2015 Tony Hunt was appointed CEO of Repligen Corporation (NASDAQ:RGEN). This report will, first, examine the CEO...
Repligen (RGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Repligen stock is the IBD Stock Of The Day as Big Pharma's drugmaking partner stays resilient amid the coronavirus pandemic. Repligen makes the tools necessary to develop drugs.
We are hunkering down, staying extremely defensive, but also looking for opportunities that may help us begin to restore our portfolios, asserts Nancy Zambell, editor of Wall Street's Best Investments.
Bet on five stocks that are likely to outdo earnings estimates.
Repligen little changed. Worling on consolidation with 110.04 buy point. Could be forming a handle.Repligen sells protein and filtration products, and chromatography tools, to biotechs and drugmakers as part of drug-making process. Stock Of The Day
The bioprocess leader relies on clinical trials for a significant portion of revenue. How disruptive will the coronavirus be?
The stock market closed near session highs Wednesday, recouping the bulk of the prior day's sharp losses. The battered oil market rebounded too.
The bioprocess equipment leader didn't see a slowdown from the coronavirus pandemic, while expected headwinds in a major business unit failed to materialize.
Q1 2020 Repligen Corp Earnings Call
As you might know, Repligen Corporation (NASDAQ:RGEN) just kicked off its latest first-quarter results with some very...
Reports record quarterly revenue of $76.1 millionOverall revenue grew 25% year-over-year, with organic growth of 16% Strong order load through first four months WALTHAM,.
RGEN earnings call for the period ending March 31, 2020.
Repligen, today's selection for IBD 50 Stocks To Watch, has both opportunities and risks related to the coronavirus pandemic.
Repligen (RGEN) delivered earnings and revenue surprises of 45.46% and 5.75%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?